Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein.
The oxidation of apolipoprotein B-containing lipoproteins and cell membrane lipids is believed to play an integral role in the development of fatty streak lesions, an initial step in atherogenesis. We have previously shown that two antioxidant-like enzymes, paraoxonase (PON)-1 and PON3, are high density lipoprotein-associated proteins capable of preventing the oxidative modification of low density lipoprotein (LDL) (Reddy, S. T., Wadleigh, D. J., Grijalva, V., Ng, C., Hama, S., Gangopadhyay, A., Shih, D. M., Lusis, A. J., Navab, M., and Fogelman, A. M. (2001) Arterioscler. Thromb. Vasc. Biol. 21, 542-547). In the present study, we demonstrate that PON2 (i) is not associated with high density lipoprotein; (ii) has antioxidant properties; and (iii) prevents LDL lipid peroxidation, reverses the oxidation of mildly oxidized LDL (MM-LDL), and inhibits the ability of MM-LDL to induce monocyte chemotaxis. The PON2 protein was overexpressed in HeLa cells using the tetracycline-inducible ("Tet-On") system, and its antioxidant capacity was measured in a fluorometric assay. Cells that overexpressed PON2 showed significantly less intracellular oxidative stress following treatment with hydrogen peroxide or oxidized phospholipid. Moreover, cells that overexpressed PON2 were also less effective in oxidizing and modifying LDL and, in fact, were able to reverse the effects of preformed MM-LDL. Our results suggest that PON2 possesses antioxidant properties similar to those of PON1 and PON3. However, in contrast to PON1 and PON3, PON2 may exert its antioxidant functions at the cellular level, joining the host of intracellular antioxidant enzymes that protect cells from oxidative stress.
Ng
C J
CJ
Atherosclerosis Research Unit, University of California, Los Angeles, California 90095-1679, USA.
Wadleigh
D J
DJ
Gangopadhyay
A
A
Hama
S
S
Grijalva
V R
VR
Navab
M
M
Fogelman
A M
AM
Reddy
S T
ST
D000975:Antioxidants / Q000494:pharmacology*; D001158:Arteries / Q000378:metabolism; D043303:Aryldialkylphosphatase; D015152:Blotting, Northern; D015153:Blotting, Western; D002478:Cells, Cultured; D002633:Chemotaxis; D003001:Cloning, Molecular; D003287:Contrast Media / Q000494:pharmacology; D004318:Doxycycline / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000378:metabolism; D004950:Esterases / Q000096:biosynthesis* / Q000502:physiology*; D019793:Fluorescein / Q000494:pharmacology; D006367:HeLa Cells; D006801:Humans; D008075:Lipoproteins, HDL / Q000378:metabolism; D008077:Lipoproteins, LDL / Q000378:metabolism*; D018384:Oxidative Stress; D010100:Oxygen / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism; D013050:Spectrometry, Fluorescence; D013997:Time Factors; D014018:Tissue Distribution; D014162:Transfection
D000975:Antioxidants; D003287:Contrast Media; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D010743:Phospholipids; D004950:Esterases; D043303:Aryldialkylphosphatase; C468411:PON2 protein, human; D004318:Doxycycline; D010100:Oxygen; D019793:Fluorescein